Back to Search Start Over

Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.

Authors :
Climent, Miguel Ángel
Álvarez, Carlos
Morales, Rafael
Maroto, Pablo
Rodríguez-Vida, Alejo
Méndez-Vidal, María José
del Muro, Xavier García
Puente, Javier
Láinez, Nuria
Vázquez, Sergio
Castellano, Daniel
Lang, Carmen Gómez
Wang, Jing
di Pietro, Alessandra
Davis, Craig
Sanz-Castillo, Belén
Bolós, M. Victoria
Valderrama, Begoña P.
Source :
Clinical & Translational Oncology; Jun2024, Vol. 26 Issue 6, p1532-1538, 7p
Publication Year :
2024

Abstract

Purpose: Post hoc analysis of the JAVELIN Bladder 100 trial of avelumab maintenance in locally advanced/metastatic urothelial carcinoma (la/mUC) to determine the interaction by programmed death ligand 1 (PD-L1) status for overall survival (OS), and additional analyses of survival per a different PD-L1 expression cutoff of ≥ 1% in tumor cells or immune cells (TC/IC). Methods: JAVELIN Bladder 100 data were used for the analysis of the interaction by PD-L1 status (per cutoff used in the trial) for OS and, additionally, OS and progression-free survival (PFS) analyses per a different ≥ 1% TC/IC PD-L1 expression cutoff (Ventana SP263 assay). Results: No significant interaction between treatment and PD-L1 status was observed for OS. Clinically meaningful and robust survival data were observed in favor of avelumab using the different ≥ 1% TC/IC PD-L1 expression cutoff. Conclusions: These results demonstrate the benefit of avelumab maintenance in la/mUC regardless of PD-L1 expression, consistent with approved labels. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1699048X
Volume :
26
Issue :
6
Database :
Complementary Index
Journal :
Clinical & Translational Oncology
Publication Type :
Academic Journal
Accession number :
178046476
Full Text :
https://doi.org/10.1007/s12094-023-03358-4